Today: 5 March 2026
Subscribe
Browse Category

Stock Market 3 November 2025

SoFi Stock Soars to New Highs After Record Earnings – Why Some Say It’s Just the Beginning

SoFi Stock Soars to New Highs After Record Earnings – Why Some Say It’s Just the Beginning

SoFi Technologies shares hit record highs near $31 after Q3 2025 revenue surged 38% to $950 million and net income more than doubled to $139 million. The company raised full-year guidance, now projecting 36% revenue growth. SoFi added 905,000 new members in the quarter, reaching 12.6 million. Wall Street remains cautious, with most analysts rating the stock Hold despite recent gains.
3 November 2025
···
Bitfarms (BITF) Skyrockets on AI Pivot – Bitcoin Miner’s 400% Rally and Future Outlook

Bitfarms (BITF) Skyrockets on AI Pivot – Bitcoin Miner’s 400% Rally and Future Outlook

Bitfarms Ltd. closed a $588 million convertible notes offering on October 21 to fund AI data center expansion, with notes convertible at $6.86 per share. Shares surged 428% in three months, reaching $4.20 in early November, and market cap stands at $2.3 billion. The company reported $245 million in trailing revenue and a net loss of $86 million. Bitfarms is shifting focus to HPC/AI amid rising mining difficulty.
3 November 2025
····
Plug Power’s High-Stakes Hydrogen Comeback: Stock Surge, CEO Shakeup & Big Deals Fuel 2025 Hopes

Plug Power’s High-Stakes Hydrogen Comeback: Stock Surge, CEO Shakeup & Big Deals Fuel 2025 Hopes

Plug Power shares traded near $2.70 on Nov. 3, 2025, rebounding from sub-$1 lows but still over 90% below 2021 highs. Q2 revenue rose 21% to $174 million, with gross margin improving to -31%. CEO Andy Marsh will step down by March 2026, succeeded by Jose Luis Crespo. The company signed a 2 GW electrolyzer deal with Allied Biofuels and expanded U.S. hydrogen and SAF partnerships.
3 November 2025
·
Record 2026 Tax Refund Surge Looms as New Tax Cuts Fuel a $50 Billion “Stimulus”

Record 2026 Tax Refund Surge Looms as New Tax Cuts Fuel a $50 Billion “Stimulus”

Americans are expected to receive tax refunds averaging $3,743—about $557 more than last year—when filing 2025 returns, due to retroactive tax cuts and unchanged IRS withholding tables. The changes, signed into law by President Trump in July, will deliver an estimated $50 billion in extra refunds, with most benefits going to higher earners. Economists warn the surge could temporarily boost consumer spending and inflation.
3 November 2025
·
Delisted Xbox 360 Games Suddenly Reappear – Backward Compatibility on the Horizon?

Delisted Xbox 360 Games Suddenly Reappear – Backward Compatibility on the Horizon?

Several previously delisted Xbox 360 games appeared on the Microsoft Store with a "Coming soon" label, despite no official announcement from Microsoft. The listings follow the July 2024 shutdown of the Xbox 360 marketplace. The move has fueled speculation about renewed backward compatibility efforts and possible emulator development. Licensing hurdles remain a barrier to reselling older titles.
3 November 2025
·
AI Chip Frenzy Sends Lam Research Soaring 117% – More Upside Ahead?

AI Chip Frenzy Sends Lam Research Soaring 117% – More Upside Ahead?

Lam Research shares have surged 117% year-to-date in 2025, far outpacing Nvidia and Broadcom. The company posted Q3 revenue of $5.32 billion, up about 28% year-over-year, and adjusted EPS jumped 46% to $1.26. Lam raised guidance for the next quarter, citing soaring demand for AI chipmaking equipment. CEO Tim Archer said AI data center investment is directly expanding Lam’s market.
3 November 2025
···
ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

ClearPoint Neuro shares surged to the mid-$20s in November 2025 after hitting a 52-week high near $30, driven by heavy trading and recent product breakthroughs. The company reported Q2 revenue of $9.2 million, up 17% year-on-year, but remains unprofitable. Its neuro devices gained expanded FDA clearance and international approvals. Analysts maintain buy ratings with price targets averaging $29.
3 November 2025
·
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers said Oct. 29 it will offer clinician-supervised GLP-1 “microdose” plans using compounded semaglutide for metabolic health, priced at $1,200 for six months. The drugs, not FDA-approved, target patients with conditions like sleep apnea or high blood pressure. Medical experts warn safety data is limited and compounded versions carry risks. HIMS stock rose 2–3% after the announcement.
3 November 2025
···
Nocera (NCRA) Stock Skyrockets 36% on $300M Digital Asset Deal – Key Facts & Outlook

Nocera (NCRA) Stock Skyrockets 36% on $300M Digital Asset Deal – Key Facts & Outlook

Nocera, Inc. announced a private placement of up to $300 million in senior secured convertible notes to fund a stablecoin-based digital asset treasury and acquisitions. Shares surged as much as 36% pre-market on November 3, 2025, hitting a new 52-week high. The Taiwan-based firm, once focused on aquaculture, has shifted to an acquisition-driven model but remains unprofitable, with revenue down 29% in 2024.
3 November 2025
·
Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

Biohaven Ltd. shares dropped over 20% in pre-market trading Nov. 3, falling to about $13.40 after closing at $17.20 on Oct. 31. The decline comes ahead of an FDA decision on troriluzole, expected in Q4 2025. The stock is down roughly 66% year-over-year, far underperforming biotech peers. Biohaven reported $408 million in cash mid-2025 but posted a $198 million net loss in Q2.
3 November 2025
·
Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals’ shares surged over 100% on November 3 after announcing positive Phase 1b results for its PH-762 skin cancer therapy, with one patient achieving full tumor clearance. No serious adverse effects were reported at any dose. The company, with a $12 million pre-rally market cap and no revenue, holds enough cash to fund operations into 2026 but will need more capital for larger trials. Analyst outlooks remain mixed.
3 November 2025
··
ON Semiconductor (ON) Stock Surges on Q3 Earnings Beat – Latest News, Financials, and Outlook

ON Semiconductor (ON) Stock Surges on Q3 Earnings Beat – Latest News, Financials, and Outlook

ON Semiconductor reported Q3 2025 net income of $255 million, or $0.63 per share, beating analyst estimates. Revenue reached $1.55 billion. The stock is down 10% year-to-date and 24% over 12 months, lagging sector gains. Analysts rate ON a “Moderate Buy,” with a $57–58 average price target, and expect a rebound in 2026 after a projected 42% EPS drop in 2025.
3 November 2025
··
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure shares plunged nearly 65% to $23–24 midday Nov. 3 after the FDA ruled current Huntington’s trial data insufficient for approval, erasing billions in market value. The company had raised $345 million in September at $47.50/share following a surge on positive trial results. Q2 revenue was $5.3 million, with a net loss of $37.7 million. Cash reserves rose to about $550 million after the equity raise.
3 November 2025
··
MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

MongoDB named Chirantan “CJ” Desai as its next CEO, replacing Dev Ittycheria, who will step down in November 2025 after 11 years. Shares jumped about 9% in pre-market trading, nearing all-time highs, as the company raised its Q3 FY2026 outlook and analysts boosted price targets. Ittycheria will stay on as an advisor during the transition. Final Q3 results are due December 1, 2025.
3 November 2025
····
Amazon Stock Skyrockets to Record High on AWS Boom – Analysts Predict More Upside

Amazon Stock Skyrockets to Record High on AWS Boom – Analysts Predict More Upside

Amazon shares hit a record high near $244 on Oct. 31, 2025, after surging almost 10% on strong Q3 results. Revenue reached $180.2 billion and net income jumped to $21.2 billion, boosted by a $9.5 billion gain from its Anthropic investment. AWS revenue grew 20% to $33 billion, easing cloud slowdown fears. Wall Street raised price targets, with some analysts now valuing Amazon near $300 per share.
3 November 2025
···
Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

Opendoor Technologies shares surged 1,300% from June lows, averting Nasdaq delisting and prompting the company to cancel a planned reverse split. Despite the rally, Opendoor posted a $29 million Q2 loss and expects Q3 revenue to fall sharply. The company named Kaz Nejatian CEO in September, shifting focus to AI-powered real estate. Wall Street analysts remain skeptical, with price targets below current levels.
3 November 2025
··
NIO Stock Skyrockets on Record Sales and Bold Moves – Can the Rally Last?

NIO Stock Skyrockets on Record Sales and Bold Moves – Can the Rally Last?

NIO delivered a record 40,397 vehicles in October 2025, up 92.6% year-over-year, pushing its stock to $7.25 after a sharp weekly rise. The company’s Onvo L90 SUV topped 10,000 units for a third month. NIO plans to expand into seven new European countries and hit 90 million battery swaps in October. Year-to-date, NIO shares are up about 60–66% but remain below 2021 highs.
3 November 2025
··
TGE Stock’s Wild Ride: Why The Generation Essentials Group Is Making Headlines in Nov 2025

TGE Stock’s Wild Ride: Why The Generation Essentials Group Is Making Headlines in Nov 2025

Generation Essentials Group (NYSE: TGE) stock plunged 54% to $0.78 on Oct. 31, 2025, then rebounded nearly 80% in early November. The company announced a $5 million share buyback and reported first-half 2025 revenue up 160% to $87.4 million. TGE holds $405 million in liabilities and faces tight liquidity, with analysts cautious and legal risks reported. The France-based media and hospitality firm went public via SPAC in mid-2025.
3 November 2025
·
IDEXX Laboratories (IDXX): Inside the Pet Diagnostics Leader’s 2025 Breakout 🚀

IDEXX Laboratories (IDXX): Inside the Pet Diagnostics Leader’s 2025 Breakout 🚀

IDEXX Laboratories reported Q3 2025 revenue of $1.11 billion, up 13%, and EPS of $3.40, up 21%, beating expectations and raising full-year guidance. Shares have surged about 50–55% year-to-date, trading near all-time highs. The company holds nearly half the global veterinary diagnostics market and generates about 79% of sales from recurring revenue. Institutional ownership stands at approximately 94%.
3 November 2025
·
Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics shares surged over 300% in a month, jumping to $2.20–$2.50 after announcing a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal brought $10 million upfront and extended Rani’s cash runway into 2028 with a $60.3 million financing. Analyst targets rose as high as $11. Trading volume spiked tenfold, with the stock breaking key technical levels.
3 November 2025
··
1 … 1,217 1,218 1,219 1,220 1,221 … 1,332
Go toTop